NLRC3在肿瘤发生发展中作用的研究进展
摘要
<正>模式识别受体(如TLR,NLR,CLR,RLR)是宿主免疫系统的重要组成部分并与肿瘤发生关系密切~([1-3])。NOD样受体(nucleotide-binding domain,leucine-rich repeat containing receptors,NLRs)是与内外源性病原或损伤相关分子模式(PAMPs、
引文
[1]Sepehri Z,Kiani Z,Kohan F,et al. Toll like receptor 4 andhepatocellular carcinoma; A systematic review[J]. Life Sci,2017,179:80-87.
[2]Nyul-Toth A,Kozma M,Nagyoszi P,et al. Expression of patternrecognition receptors and activation of the non-canonicalinflammasome pathway in brain pericytes[J]. Brain Behav Immun,2017,64:220-231.
[3]Kutikhin AG,Yuzhalin AE. Inherited variation in patternrecognition receptors and cancer:dangerous liaisons?[J]. CancerManag Res,2012,4:31-38.
[4]Allen IC. Non-Inflammasome Forming NLRs in Inflammation andTumorigenesis[J]. Frontiers in Immunology,2014,5:169.
[5]Gao FY,Pang JC,Lu MX,et al. Molecular characterization,expression and functional analysis of NOD1,NOD2 and NLRC3 inNile tilapia(Oreochromis niloticus)[J]. Fish Shellfish Immunol,2018,73:207-219.
[6]Conti BJ,Davis BK,Zhang J,et al. CATERPILLER 16.2(CLR16.2),a novel NBD/LRR family member that negatively regulates Tcell function[J]. J Biol Chem,2005,280(18):18375-18385.
[7]Karki R,Man SM,Malireddi RK,et al. NLRC3 is an inhibitorysensor of PI3K-mTOR pathways in cancer[J]. Nature,2016,540(7634):583-587.
[8]Schneider M,Zimmermann AG,Roberts RA,et al. The innateimmune sensor NLRC3 attenuates Toll-like receptor signaling viamodification of the signaling adaptor TRAF6 and transcriptionfactor NF-kappaB[J]. Nat Immunol,2012,13(9):823-831.
[9]Zhang L,Mo J,Swanson KV,et al. NLRC3,a member of the NLRfamily of proteins,is a negative regulator of innate immunesignaling induced by the DNA sensor STING[J]. Immunity,2014,40(3):329-341.
[10]G¨1ltekin Y,Eren E,Z?Ren N. Overexpressed NLRC3 acts as ananti-inflammatory cytosolic protein[J]. J Innate Immun,2015,7(1):25-36.
[11]Liu R,Truax AD,Chen L,et al. Expression profile of innateimmune receptors,NLRs and AIM2,in human colorectal cancer:correlation with cancer stages and inflammasome components[J].Oncotarget,2015,6(32):33456-33469.
[12]Global,regional,and national comparative risk assessment of 79behavioural,environmental and occupational,and metabolic risksor clusters of risks,1990-2015:a systematic analysis for theGlobal Burden of Disease Study 2015[J]. Lancet,2016,388(10053):1659-1724.
[13]程明,梁怡明,邬林泉.非典型蛋白激酶表达与胰腺癌相关性的研究[J].江西医药,2018,53(8):818-821.
[14]刘国栋,李昌荣,等.早期胃癌淋巴结转移相关危险因素的研究[J].江西医药,2016,51(3):227-231.
[15]杨文泰.胃蛋白酶原与胃部疾病相关性的研究进展[J].江西医药,2018,53(4):398-400.
[16]丁祥利,严菊梅,廖旺娣.炎症性肠病与机会性感染[J].江西医药,2018,53(2):173-178.
[17]刘承远,陈海鸣. IL-10、TNF-α在脓毒症小鼠小肠黏膜中的表达及其意义[J].江西医药,2015,50(11):1173-1175.
[18]兰静,周峰.不同炎性因子在慢性阻塞性肺疾病中表达的研究进展[J].江西医药,2015,50(10):1127-1129.
[19]Hu S,Du X,Huang Y,et al. NLRC3 negatively regulates CD4+Tcells and impacts protective immunity during Mycobacteriumtuberculosis infection[J]. Plos Pathogens,2018,14(8):e1007266.
[20]Allen IC,Wilson JE,Schneider M,et al. NLRP12 suppressescolon inflammation and tumorigenesis through the negativeregulation of noncanonical NF-κB signaling[J]. Immunity,2012,36(5):742-754.
[21]Ma YY,Zhang GH,Li J,et al. The correlation of NLRC3expression to the progression and prognosis of hepatocellularcarcinoma[J]. Hum Pathol,2018,82:273-281.
[22]Ersahin T,Tuncbag N,Cetin-Atalay R. The PI3K/AKT/mTORinteractive pathway[J]. Mol Biosyst,2015,11(7):1946-1954.
[23]王洁.EGCG通过调节mTOR途径下游S6K1和4e-BP1因子抑制宫颈癌HeLa细胞分生[D].浙江大学,2015.
[24]Karki R,Malireddi RKS,Zhu Q. NLRC3 regulates cellularproliferation and apoptosis to attenuate the development ofcolorectal cancer[J],2017,16(13):1243-1251.
[25]王鑫,支修益.国际肺癌研究协会(IASLC)第八版肺癌TNM分期解读[J].中华胸部外科电子杂志,2016,3(2):70-76.
[2]Nyul-Toth A,Kozma M,Nagyoszi P,et al. Expression of patternrecognition receptors and activation of the non-canonicalinflammasome pathway in brain pericytes[J]. Brain Behav Immun,2017,64:220-231.
[3]Kutikhin AG,Yuzhalin AE. Inherited variation in patternrecognition receptors and cancer:dangerous liaisons?[J]. CancerManag Res,2012,4:31-38.
[4]Allen IC. Non-Inflammasome Forming NLRs in Inflammation andTumorigenesis[J]. Frontiers in Immunology,2014,5:169.
[5]Gao FY,Pang JC,Lu MX,et al. Molecular characterization,expression and functional analysis of NOD1,NOD2 and NLRC3 inNile tilapia(Oreochromis niloticus)[J]. Fish Shellfish Immunol,2018,73:207-219.
[6]Conti BJ,Davis BK,Zhang J,et al. CATERPILLER 16.2(CLR16.2),a novel NBD/LRR family member that negatively regulates Tcell function[J]. J Biol Chem,2005,280(18):18375-18385.
[7]Karki R,Man SM,Malireddi RK,et al. NLRC3 is an inhibitorysensor of PI3K-mTOR pathways in cancer[J]. Nature,2016,540(7634):583-587.
[8]Schneider M,Zimmermann AG,Roberts RA,et al. The innateimmune sensor NLRC3 attenuates Toll-like receptor signaling viamodification of the signaling adaptor TRAF6 and transcriptionfactor NF-kappaB[J]. Nat Immunol,2012,13(9):823-831.
[9]Zhang L,Mo J,Swanson KV,et al. NLRC3,a member of the NLRfamily of proteins,is a negative regulator of innate immunesignaling induced by the DNA sensor STING[J]. Immunity,2014,40(3):329-341.
[10]G¨1ltekin Y,Eren E,Z?Ren N. Overexpressed NLRC3 acts as ananti-inflammatory cytosolic protein[J]. J Innate Immun,2015,7(1):25-36.
[11]Liu R,Truax AD,Chen L,et al. Expression profile of innateimmune receptors,NLRs and AIM2,in human colorectal cancer:correlation with cancer stages and inflammasome components[J].Oncotarget,2015,6(32):33456-33469.
[12]Global,regional,and national comparative risk assessment of 79behavioural,environmental and occupational,and metabolic risksor clusters of risks,1990-2015:a systematic analysis for theGlobal Burden of Disease Study 2015[J]. Lancet,2016,388(10053):1659-1724.
[13]程明,梁怡明,邬林泉.非典型蛋白激酶表达与胰腺癌相关性的研究[J].江西医药,2018,53(8):818-821.
[14]刘国栋,李昌荣,等.早期胃癌淋巴结转移相关危险因素的研究[J].江西医药,2016,51(3):227-231.
[15]杨文泰.胃蛋白酶原与胃部疾病相关性的研究进展[J].江西医药,2018,53(4):398-400.
[16]丁祥利,严菊梅,廖旺娣.炎症性肠病与机会性感染[J].江西医药,2018,53(2):173-178.
[17]刘承远,陈海鸣. IL-10、TNF-α在脓毒症小鼠小肠黏膜中的表达及其意义[J].江西医药,2015,50(11):1173-1175.
[18]兰静,周峰.不同炎性因子在慢性阻塞性肺疾病中表达的研究进展[J].江西医药,2015,50(10):1127-1129.
[19]Hu S,Du X,Huang Y,et al. NLRC3 negatively regulates CD4+Tcells and impacts protective immunity during Mycobacteriumtuberculosis infection[J]. Plos Pathogens,2018,14(8):e1007266.
[20]Allen IC,Wilson JE,Schneider M,et al. NLRP12 suppressescolon inflammation and tumorigenesis through the negativeregulation of noncanonical NF-κB signaling[J]. Immunity,2012,36(5):742-754.
[21]Ma YY,Zhang GH,Li J,et al. The correlation of NLRC3expression to the progression and prognosis of hepatocellularcarcinoma[J]. Hum Pathol,2018,82:273-281.
[22]Ersahin T,Tuncbag N,Cetin-Atalay R. The PI3K/AKT/mTORinteractive pathway[J]. Mol Biosyst,2015,11(7):1946-1954.
[23]王洁.EGCG通过调节mTOR途径下游S6K1和4e-BP1因子抑制宫颈癌HeLa细胞分生[D].浙江大学,2015.
[24]Karki R,Malireddi RKS,Zhu Q. NLRC3 regulates cellularproliferation and apoptosis to attenuate the development ofcolorectal cancer[J],2017,16(13):1243-1251.
[25]王鑫,支修益.国际肺癌研究协会(IASLC)第八版肺癌TNM分期解读[J].中华胸部外科电子杂志,2016,3(2):70-76.